View Older Stories View More Recent Stories
-
Publication relating to a transparency notification
-
Publication relating to a transparency notification
-
Moving Minds Launches New Fractional Chief Marketing Officer (CMO) Practice
-
Ribon Therapeutics Secures $65 Million Financing
-
Portable MRI Startup Hyperfine is Going Public After SPAC Merger With HealthCor Catalio
-
Hyperfine and Liminal Sciences to Be Listed on Nasdaq Through a Business Combination With HealthCor Catalio Acquisition Corp. (HCAQ)
-
Hyperfine, Inc., Creator of the First FDA-Cleared Portable MRI Device, and Liminal Sciences, Inc. To Be Listed on Nasdaq Through a Business Combination With HealthCor Catalio Acquisition Corp.
-
Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management
-
DFP Healthcare Acquisitions Corp. (DFPH) Announces Proposed Business Combination With The Oncology Institute
-
DFP Healthcare Acquisitions Corp. Announces Proposed Business Combination With The Oncology Institute
-
Novocardia™ Announces $53.7 Million Financing Led by Deerfield Management
-
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
-
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
-
Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer and Other Diseases
-
Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus
-
Demy-Colton Announces BioFuture™ Conference to be held at Cure, Deerfield’s Vertical Innovation Campus in New York City
-
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
-
Form SC 13D/A Deerfield Healthcare Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform
-
Deerfield Healthcare Technology Acquisitions Corp. (DFHT) Announces Closing of Business Combination With CareMax (CMAX)
-
Deerfield Healthcare Technology Acquisitions Corp. Announces Closing of Business Combination With CareMax
-
Deerfield Healthcare Technology Acquisitions Corp. Announces Stockholder Approval of Business Combination With CareMax
-
Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting
-
Form 3 Singular Genomics System For: May 26 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Larimar Therapeutics (LRMR) Announces $95 Million Private Placement Financing of Common Stock, Warrants
-
Larimar Therapeutics Announces $95 Million Private Placement Financing
-
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
-
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
-
Form 4 Larimar Therapeutics, For: May 12 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Form 13F-HR DEERFIELD MANAGEMENT For: Mar 31
-
Deerfield Management and Baylor College of Medicine Announce Blue Square Discoveries to Advance Novel Therapeutic Treatments
-
Miravo Healthcare™ Announces First Quarter 2021 Results
-
DFHT Announces Special Meeting of Stockholders to Vote on Business Combination to be held on June 4, 2021
-
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
-
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
-
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
-
Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing
-
Endologix LLC Announces Launch of ALTO® Abdominal Stent Graft System in Canada and Argentina
-
Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
-
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
-
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
-
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021
-
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
-
Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar
-
Empire Discovery Institute (EDI) and Deerfield Management Launch Empire-Deerfield Discovery & Development (ED³) LLC
-
Nuo Therapeutics Announces Publication of Final Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds by Centers for Medicare & Medicaid Services
-
Lumos Pharma (LUMO) Announces Retirement of Carl Langren and Names Lori Lawley CFO in Planned Succession
-
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
-
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
